Fresenius Kabi Compounding Recalls Acyclovir Sodium Injection Due to Sterility Concerns
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Fresenius Kabi Compounding, LLC has voluntarily recalled 1,057 bags of acyclovir sodium injection distributed nationwide due to a lack of assurance of sterility.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Fresenius Kabi Compounding, LLC (operating as Fagron Sterile Services) has initiated a voluntary recall of acyclovir sodium added to 0.9% Sodium Chloride Injection. The recall was prompted by a lack of assurance of sterility for the affected lot, which could pose significant health risks to patients receiving the intravenous medication.
Which Products Are Affected
The recall involves specific bags of acyclovir sodium for intravenous use. The following details identify the affected product:
- Product Name: acyclovir sodium, 200 mg (200mg added to 100 mL), 0.9% Sodium Chloride Injection, USP
- Packaging: Single-Use Bag
- NDC: 71506-035-56
- Lot Number: C274-000049124
- Expiration Date: 28-Feb-26
- Quantity: 1,057 bags
- Distribution: Distributed nationwide across the United States.
What You Should Do
Healthcare providers and medical facilities should immediately inspect their inventory for the affected lot number (C274-000049124). Any units from this lot should be quarantined and not administered to patients. The firm initiated the recall via notification letters; facilities should follow the specific instructions provided in those communications for the return or disposal of the affected products.
Why This Matters
A lack of assurance of sterility in an intravenous drug is a serious safety concern. Contaminated products injected directly into the bloodstream can lead to severe infections, systemic illness, or other life-threatening medical complications.
Source
This information is based on official recall data provided by the FDA (Recall Number: D-0333-2026).
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.